Important issues that need to be clarified for serum CXCL13 to be established as an additional biomarker include demonstration of whether circulating levels of the chemokine reliably reflect synovial synthesis and different synovial pathotypes and how well they outperform currently available tests in the clinical assessment and prognostic stratification of RA. Here, CXCL13 is linked to rheumatoid arthritis.